Selected Grants
A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION STUDY OF SGR-1505 AS MONOTHERAPY IN SUBJECTS WITH MATURE B-CELL MALIGNANCIES
Clinical TrialPrincipal Investigator · Awarded by Schrodinger, Inc. · 2024 - 2029INCB50465-801 Rollover (7008420
Clinical TrialPrincipal Investigator · Awarded by Incyte Corporation · 2023 - 2028Viracta: An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
Clinical TrialPrincipal Investigator · Awarded by Viracta Therapeutics, Inc. · 2023 - 2028An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients with Waldenstrom Macroglobulinemia (CLOVER-WaM)
Clinical TrialPrincipal Investigator · Awarded by Cellectar Biosciences, Inc. · 2023 - 2028PHASE III RANDOMIZED, OPEN-LABEL,MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE IN PATIENTS WITH FOLLICULAR LYMPHOMA AFTER AT LEAST ONE
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2022 - 2027A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF GLOFITAMAB IN COMBINATION WITH GEMCITABINE
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2021 - 2026LOXO Oncology study
Clinical TrialPrincipal Investigator · Awarded by Loxo Oncology, Inc. · 2020 - 2025Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Roituximab and Chemotherapy
Clinical TrialPrincipal Investigator · Awarded by Atara Biotherapeutics, Inc. · 2020 - 2025A PHASE I/II TRIAL OF MOSUNETUZUMAB (BTCT4465A) AS CONSOLIDATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FOLLOWING FIRST-LINE IMMUNOCHEMOTHERAPY AND AS THERAPY IN PATIENTS WITH PREVIOUS
Clinical TrialPrincipal Investigator · Awarded by Genentech, Inc. · 2019 - 2024A multicenter retrospective non-interventional follow-up study in patients with sickle cell pain crisis who previously participated in the SUSTAIN trial in the United States
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2020 - 2024LYMRIT 37-01
Clinical TrialPrincipal Investigator · Awarded by Nordic Nanovector ASA · 2019 - 2023A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB-50465, a PI3K8 Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Clinical TrialPrincipal Investigator · Awarded by Incyte Corporation · 2018 - 2023A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma
Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2013 - 2023A Phase 2a Open-label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractor
Clinical TrialPrincipal Investigator · Awarded by Molecular Templates, Inc. · 2019 - 2023BeiGene BGB-3111-212 An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined with Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma
Clinical TrialPrincipal Investigator · Awarded by BeiGene, Ltd · 2018 - 2023Advancing Cancer Care in the Rural Southeast: Enhancing Precision Medicine and Institutional Collaboration in Community Cancer Centers
ResearchCollaborator · Awarded by V Foundation for Cancer Research · 2021 - 2023Partnership to Support the Duke Molecular Tumor Board Program
Inst. Training Prgm or CMECollaborator · Awarded by Bayer Healthcare Pharmaceuticals Inc · 2020 - 2022A Single Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphome (FL)
ResearchPrincipal Investigator · Awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership · 2014 - 2022Phase 3 Randomized Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) R-Chop Chemotherapy (R2-Chop) versus Placebo plus R-Chop Chemotherapy in Subjects with previously untreated Lymphoma
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2015 - 2022Advancing Cancer Care in the Rural Southeast: Delivering Novel Therapies In Our Community Cancer Centers
ResearchCollaborator · Awarded by V Foundation for Cancer Research · 2019 - 2021Long Term Follow-Up Study of Clinical Study Subjects Treated with ACTR087, Autologous T Cells Expressing Antibody-Coupled T-Cell Receptors
Clinical TrialPrincipal Investigator · Awarded by Unum Therapeutics Inc. · 2017 - 2021Phase I Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Couple T-Cell Receptors (CD16V-41BB-CD35), in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma
ResearchPrincipal Investigator · Awarded by Unum Therapeutics Inc. · 2016 - 2021Denovo DB102-02 A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1¿
Clinical TrialPrincipal Investigator · Awarded by Denovo Biopharma, LLC · 2018 - 2021A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI13K Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)
Clinical TrialPrincipal Investigator · Awarded by Incyte Corporation · 2018 - 2020Randomized, Open-label, Phase 3 Trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone Participatns with Relasped Refractory or Ineligible for Autologous Stem Cell Transplant
Clinical TrialPrincipal Investigator · Awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership · 2018 - 2020Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma
Clinical TrialPrincipal Investigator · Awarded by Pharmacyclics, Inc. · 2018 - 2020A Phase 2, Open-Label, 2-C Cohort Study of INCB050465, A P13K@ Inhibitor, in Subjects with Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)
Clinical TrialPrincipal Investigator · Awarded by Incyte Corporation · 2017 - 2020Phase 1 Trial of Panobinostat + Ruxolitnib for Relapsed/Refactory Diffused Large B Cell Lymphoma (DLBCL)
ResearchPrincipal Investigator · Awarded by Lymphoma Research Foundation of America · 2016 - 2019A Phase 1/2 Study Evaluating Brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma
Clinical TrialPrincipal Investigator · Awarded by Seattle Genetics, Inc · 2016 - 2019A Randomized Open Label Phase 2 Study of Denintuzumab mafodotin (SGN -CD19A)
Clinical TrialPrincipal Investigator · Awarded by Seattle Genetics, Inc · 2016 - 2019Novel combinations to overcome resistance to histone deacetylase inhibitors in lymphoma
ResearchFellow · Awarded by Leukemia & Lymphoma Society · 2015 - 2016External Relationships
- ADC therapeutics
- BeiGene
- Epizyme
- Incyte
- Kite pharmaceuticals (Gilead)
- Roche/Genentech
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.